Cambridge, Mass.-based Archemix Corp. says it plans to issue 4.5 million shares of stock in its IPO, which is intended to raise about $64 million. The funds will be used for R&D for new preclinical and clinical drug candidates including aptamer products for cardiovascular disease, blood disorders and cancer.

Full Story:
MSN Money

Related Summaries